Effect of Dexamethasone on the Release of Transforming Growth Factor-Β1, Interleukin-8, Interleukin-10 and RANTES Release by Sputum Cells in Severe Asthma
Gai Xiao-yan,Sun Yong-chang,Cao Wen-li
DOI: https://doi.org/10.1097/00029330-200609020-00011
IF: 6.133
2006-01-01
Chinese Medical Journal
Abstract:Bronchial asthma is a reversible obstructive airway disease characterized by persistent airway inflammation and airway remodeling, with eosinophil infiltration of the airway walls as the predominant feature. However, our previous work1,2 and other reports3,4 have demonstrated that neutrophil predominant inflammation is present in a subgroup of asthmatics, particularly severe asthmatics, and patients with airway neutrophilia are less responsive to glucocorticoid therapy. The mechanisms underlying airway neutrophilia in asthma are still under investigation, but interleukin (IL)-8 as an important neutrophil chemokine may play an important role. Recent studies have confirmed the presence of airway remodeling in both mild and more severe asthma, although the mechanisms are still unclear. Transforming growth factor (TGF)-β1, a potent profibrotic cytokine, was found to be highly expressed in airway tissues of patients with asthma,5 and was not inhibited by treatment with glucocorticoids.6 Studies have shown that eosinophils are capable of producing TGF-β1,5 and recently, Chu et al7 demonstrated that airway neutrophils from patients with asthma also expressed very high levels of this cytokine, suggesting the role of neutrophils in airway remodeling. Considering the relative unresponsive-ness of asthmatic neutrophilic inflammation to glucocorticoid therapy,4 it is intriguing to postulate that the ongoing airway remodeling in asthmatics even receiving regular glucocorticoid therapy may be, at least partly, associated with neutrophils and related cytokines. To explore the possible roles of different inflammatory cells and cytokines in airway inflammation and remodeling in patients with severe asthma, we observed the in vitro release of TGF-β1, IL-8, IL-10, and RANTES (Regulated upon activation, normal T cell expressed and secreted) by sputum cells freshly isolated from both severe and mild asthmatic patients receiving inhaled glucocorticoids, as well as the effect of dexamethasone (DEX) on the cytokines release. METHODS Study subjects Patients with persistent asthma were recruited from the outpatient clinic of our hospital. The diagnosis and severity categorization of asthma was based on published guidelines.8 All patients had received inhaled glucocorticoids for more than 3 months before enrollment (budesonide, AstraZeneca, Sweden; 200 μg/d for mild asthma and 800 μg/d for severe asthma), and continued the therapy at the time of sputum induction. Healthy volunteers without a history of asthma and with a normal lung spirometry served as the normal controls. Both the patients and the normal controls were not smokers, without a history of respiratory infection in 6 weeks, had not received systemic glucocorticoids within 3 months, and without concomitant diseases. Written informed consent was obtained from each subject. Sputum induction and sputum cell culture Induced sputum was obtained as described in our previous report.2 Briefly, a puff of salbutamol (200 μg) was given to patients with asthma 15 minutes before the procedure. Sputum was induced by inhalation of 4% hypertonic saline by an ultrasonic nebulizer. The sputum was collected and 0.1% dithiothreitol was added for homogenization. After centrifugation at 1500 r/min for 10 minutes, the cell pellet was resuspended with PBS for total cell count. An aliquot of the cell suspension was cytospined and stained with Wright-Giemsa for cell differentials. Sputum cell culture was performed according to the protocol described by Profita et al.9 Briefly, cell pellets were resuspended in culture media consisting of RPMI 1640 (Gibco, USA), 10% heat-inactivated fetal calf serum (Hyclone, USA), and 1% penicillin-streptomycin solution at a concentration of 1.0×106 cells/ml. The cells were divided into 2 cultures, 1 without DEX (Sigma, UK; as the blank) to observe the spontaneous release of cytokines, and 1 with DEX (10-6 mol/L) to observe the effect of DEX. The cells were cultured at 37°C, 5% CO2 for 12 hours. At the end of the culture, the cell viability was >85% as assessed by trypan blue exclusion. The supernatants were then harvested and stored at —70°C for further analysis. Cytokines measurement TGF-β1, IL-8, IL-10 (R&D, Distributed by Jingmei Biochem, China) and RANTES (R&D, Minneapolis, USA) were measured by enzyme linked immunoassay kits according to instructions provided by the manufacturers. The detection limits of TGF-β1, IL-8, IL-10 and RANTES were 15 pg/ml, 3 pg/ml, 31.5 pg/ml and 2 pg/ml, respectively. Statistical analysis Data were expressed as mean±standard deviation (SD) or median (quartiles). Differences among the subject groups were analyzed by one way ANOVA and subsequently by post hoc tests. Differences between cultures with and without DEX were analyzed with two-related-sample Wilcoxon rank-sum test. Correlations were performed using Spearman rank correlation coefficients. A P value of less than 0.05 was regarded statistically significant. RESULTS Demographic data and sputum cell differentials Eighteen patients with asthma (5 mild and 13 severe) and 6 normal controls were enrolled in the study. The demographic data, the predicted percent of forced expiratory volume in 1 second (FEV1%pred) and the sputum cell differentials are shown in Table 1. The percentages of eosinophils and neutrophils were higher in asthmatics than those in normal controls (P<0.05), and the percentage of neutrophils was significantly higher in severe asthmatics compared with mild asthmatics (P<0.05).Table 1: Demographic, FEV1%pred and sputum cell dataRelease of TGF-β1, IL-8, IL-10 and RANTES by sputum cells and the effect of DEX As shown in Table 2, the amounts of TGF-β1 released spontaneously from sputum cells of both severe and mild asthmatics were significantly higher compared with normal controls (P<0.05), and it was higher in mild asthmatics than that in severe asthmatics (P<0.05). DEX treatment showed no significant effect on the release of TGF-β1 (P>0.05).Table 2: The spontaneous release of TGF-β1 and IL-8 by sputum cells from asthmatics and the effect of dexamethasone (DEX)Sputum cells from severe asthmatics spontaneously released higher amount of IL-8 compared with both mild asthmatics and normal controls (P<0.05), but the difference between the latter two was not significant (P>0.05). The change of IL-8 after DEX treatment was not statistically significant (Table 2). The amount of RANTES released spontaneously from sputum cells of severe and mild asthmatics combined [3.22 (1.66–17.55) pg/ml] tended to be higher than that from normal controls [0.42 (0.00 — 6.40) pg/ml], but the difference did not reach significance (P=0.177); and it was not different between mild [3.73 (0.00–8.08) pg/ml] and severe asthmatics [3.48 (2.47–63.69) pg/ml, P=0.289]. DEX treatment significantly decreased the amount of RANTES [2.59 (0.00–8.17) pg/ml, P =0.019] released from sputum cells of severe and mild asthmatics combined. The amount of IL-10 released from sputum cells was not different among normal controls [50.00 (37.15— 225.84) pg/ml], mild asthmatics [55.37 (32.75–109.49) pg/ml] and severe asthmatics [77.30 (44.90 -318.89) pg/ml; P>0.05]. The change of IL-10 after DEX treatment was not statistically significant [50.00 (31.36–291.86), 26.67 (19.19–88.81), 106.24 (49.45–268.70) pg/ml, respectively; all P>0.05]. Correlation results The percentage of sputum neutrophils was inversely correlated to FEV1%pred (r = -0.651, P<0.01). The spontaneously released amount of IL-8 was correlated inversely with FEV1%pred (r = — 0.681, P<0.01), but positively with the percentage of neutrophils (r=0.545, P<0.01). The spontaneously released amount of TGF-β1 was correlated positively with both neutrophils (r=0.530, P<0.01) and eosinophils (r=0.632, P<0.01). DISCUSSION The eosinophil chemotactic cytokine RANTES, produced by a variety of inflammatory cells and airway structural cells (for example, epithelial cells), has been demonstrated to play important roles in the pathogenesis of asthma. Glucocorticoid therapy is effective in inhibiting its production and release.10 Our study confirms this observation by culture of freshly isolated sputum cells from mild and severe asthmatics. Profita et al9,10 studied the in vitro effect of glucocorticoids on the release of IL-8, TGF-β1 and RANTES by sputum cells from patients with mild to moderate asthma, and found that high amounts of these cytokines were spontaneously released from the cells and glucocorticoids were able to inhibit their release. We extended this study to patients with both mild and severe asthma, and confirmed the spontaneously release of high amounts of IL-8 and TGF-β1 by sputum cells from asthmatics, but not from normal controls. We also found that the amount of IL-8 was significantly higher in patients with severe asthma than that in patients with mild asthma, and was positively correlated with the percentage of neutrophils. This result is consistent with our previous report2 and provides further evidence that IL-8 may play an important part in the airway neutrophilic inflammation of severe asthma. It is demonstrated that TGF-β1 is highly expressed in airway tissues of asthma,5,6 and reaches high levels in bronchoalveolar lavage fluid after allergen challenge.11 However, the detection of this cytokine in sputum samples was rarely reported.12 We found in this study that the amount of TGF-β1 released by sputum cells from asthmatics receiving gluco-corticoid therapy was significantly higher than that from normal controls, and the release was not inhibited by DEX treatment. In addition, to our surprise, the amount of spontaneously released TGF-β1 was higher in mild asthmatics compared with severe asthmatics. Whether this difference was due to disease severity, or to the different doses of inhaled glucocorticoids, cannot be concluded from this study. The study by Profita et al9,10 showed that glucocorticoids were able to inhibit TGF-β1 and IL-8 release, but their patients were mild to moderate asthmatics and inhaled or oral glucocorticoids had been withdrawn at least 2 months before the study. In fact, in our study, DEX treatment decreased, though not significantly, the amount of TGF-β1 from sputum cells of mild asthmatics, suggesting that the higher basal level of TGF-β1 in mild asthmatics was possibly associated with the lower doses of inhaled glucocorticoids they had received. Contrary to results from these ex vivo studies, in vivo studies did not demonstrate decreased TGF-β1 expression in airway tissues after glucocorticoid therapy.6,13 Considering the inconsistent results obtained from different studies, the effect of glucocorticoids on TGF-β1 expression and production still needs further investigation. It should be noted that, the patients with severe asthma were older than the normal controls in this study, and therefore one may ask if the difference in the basal level of TGF-β1 was associated with age. However, in a study by Young et al,14 the serum level of TGF-β1 was not correlated with age in a group of normal blood donors aged 20 to 58 years. Airway levels of IL-10 or its mRNA in asthma have been reported to be increased15,16 or decreased17 or unchanged;18 and recent studies have shown that glucocorticoid treatment can enhance IL-10 production in asthma,19 or only in glucocorticoid-sensitive asthma.20 In our study, the amount of IL-10 released from sputum cells of asthmatic patients receiving inhaled glucocorticoid therapy was not different with compared with normal controls, and DEX treatment did not change its production significantly. From the different observations mentioned above, it is suggested that the changes of IL-10 in asthmatic airways may be complicated and its role in regulation of airway inflammation needs further study in carefully selected patients. In conclusion, our study confirmed the applicability of sputum cell culture in evaluating cytokine profiles in asthmatic airways. The high amount of TGF-β1 and IL-8 release by sputum cells from severe asthmatics despite inhaled glucocorticoid therapy implies that these cytokines may be involved in the persistent airway inflammation and remodeling in asthma. The results also suggest that further investigation is needed to elucidate the expression pattern and the possible role of anti-inflammatory cytokines such as IL-10 and TGF-β1 in asthma.